title: Evoked potentials and neuropsychological tests validate Positron Emission Topography (PET) brain metabolism in cognitively impaired patients.
abstract: Fluorodeoxyglucose (FDG) Positron Emission Topography (PET) brain hypometabolism (HM) correlates with diminished cognitive capacity and risk of developing dementia. However, because clinical utility of PET is limited by cost, we sought to determine whether a less costly electrophysiological measure, the P300 evoked potential, in combination with neuropsychological test performance, would validate PET HM in neuropsychiatric patients. We found that patients with amnestic and non-amnestic cognitive impairment and HM (n = 43) evidenced significantly reduced P300 amplitudes, delayed latencies, and neuropsychological deficits, compared to patients with normal brain metabolism (NM; n = 187). Data from patients with missing cognitive test scores (n = 57) were removed from the final sample, and logistic regression modeling was performed on the modified sample (n = 173, p = .000004). The logistic regression modeling, based on P300 and neuropsychological measures, was used to validate membership in the HM vs. NM groups. It showed classification validation in 13/25 HM subjects (52.0%) and in 125/148 NM subjects (84.5%), correlating with total classification accuracy of 79.8%. In this paper, abnormal P300 evoked potentials coupled with cognitive test impairment validates brain metabolism and mild/moderate cognitive impairment (MCI). To this end, we cautiously propose incorporating electrophysiological and neuropsychological assessments as cost-effective brain metabolism and MCI indicators in primary care. Final interpretation of these results must await required additional studies confirming these interesting results.
authors.affiliation: Department of Clinical Neurology, PATH Foundation NY, New York, New York, United States of America. info@pathfoundationny.org
authors.forename: Eric R
authors.initials: ER
authors.lastname: Braverman
authors.forename: Kenneth
authors.initials: K
authors.lastname: Blum
authors.forename: Uma J
authors.initials: UJ
authors.lastname: Damle
authors.forename: Mallory
authors.initials: M
authors.lastname: Kerner
authors.forename: Kristina
authors.initials: K
authors.lastname: Dushaj
authors.forename: Marlene
authors.initials: M
authors.lastname: Oscar-Berman
mesh_terms: D000328:Adult; D000368:Aged; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism*; D003072:Cognition Disorders / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000523:psychology; D060825:Cognitive Dysfunction / Q000000981:diagnostic imaging / Q000378:metabolism / Q000523:psychology; D018913:Event-Related Potentials, P300; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008875:Middle Aged; D009483:Neuropsychological Tests; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18